MilliporeSigma
  • Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.

Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.

Biopharmaceutics & drug disposition (2014-09-30)
Mikiko Tsukimoto, Rikiya Ohashi, Nao Torimoto, Yoko Togo, Takashi Suzuki, Toshio Maeda, Yoshiyuki Kagawa
ABSTRACT

Aliskiren is a substrate for P-glycoprotein (P-gp) and is metabolized via cytochrome P450 3A4 (CYP3A4). The aim of the present study was to assess whether P-gp influenced the pharmacokinetics of aliskiren and also if drug-drug interactions (DDIs) mediated through P-gp could be reproduced in cynomolgus monkeys. The study investigated the pharmacokinetics of aliskiren in mdr1a/1b gene-deficient (P-gp KO) and wild-type (WT) mice. The area under the plasma concentration-time curve (AUC) following the oral administration of aliskiren was 6.9-fold higher in P-gp KO mice than in WT mice, while no significant differences were observed in the AUC or total plasma clearance following the intravenous administration of aliskiren to P-gp KO mice. Then the pharmacokinetics of aliskiren were evaluated and DDIs between aliskiren and P-gp inhibitors, such as cyclosporin A (CsA) and zosuquidar, examined in cynomolgus monkeys. The AUC for aliskiren were 8.3- and 42.1-fold higher after the oral administration of aliskiren with the concomitant oral administration of zosuquidar and CsA at doses of 10 and 30 mg/kg, respectively. In contrast, the AUC after the intravenous and oral administration of aliskiren was not significantly affected by the oral administration of zosuquidar or intravenous administration of CsA, respectively. These results indicated that P-gp strictly limited the intestinal absorption of aliskiren in mice and monkeys, and also that the effects of intestinal P-gp inhibition by CsA or zosuquidar on the pharmacokinetics of aliskiren were sensitively reproduced in monkeys. In conclusion, aliskiren can be used as a sensitive substrate to evaluate intestinal P-gp inhibition in monkeys.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ethylene glycol, analytical standard
Sigma-Aldrich
Ethylene glycol, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Carbamazepine, meets USP testing specifications
Sigma-Aldrich
Carbamazepine, powder
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
Sigma-Aldrich
Acetaldehyde diethyl acetal, 99%
Sigma-Aldrich
Ethylene glycol, anhydrous, 99.8%
Sigma-Aldrich
Quinidine sulfate salt dihydrate
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Colchicine, (European Pharmacopoeia (EP) Reference Standard)
Ketoconazole, European Pharmacopoeia (EP) Reference Standard
Supelco
Carbamazepine, analytical standard
Supelco
Ketoconazole, Pharmaceutical Secondary Standard; Certified Reference Material
Carbamazepine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ethylene glycol, spectrophotometric grade, ≥99%
Sigma-Aldrich
Ethylene glycol, ReagentPlus®, ≥99%
Supelco
Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ethylene glycol, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ethylene glycol, United States Pharmacopeia (USP) Reference Standard
USP
Carbamazepine, United States Pharmacopeia (USP) Reference Standard
USP
Ketoconazole, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, ≥95%
Sigma-Aldrich
Cyclosporin A, from Tolypocladium inflatum, ≥95% (HPLC), solid
Sigma-Aldrich
Colchicine, BioReagent, suitable for plant cell culture, ≥95% (HPLC)
Sigma-Aldrich
Colchicine, ≥95% (HPLC), powder
Sigma-Aldrich
Ketoconazole, 99.0-101.0% (EP, titration)
Sigma-Aldrich
Acetal, ≥98%, FG